1. ALLA AKTIER
  2. NYHETER
  3. NANEXA

Nanexa

Nyheter Nanexa Nyheter alla bolag

All patients in Nanexa Phase 1 study of NEX-22 dosed according to plan

Nanexa AB today announces that dosing of the last patient has been completed in the Phase 1 study of the long-acting depot formulation of the GLP-1 analog liraglutide PharmaShell®.

The dosing of NEX-22 in patients with Type 2 Diabetes was completed by end of September at the clinical site in Germany in the third and last dose group. Data from the two first dose groups of the PharmaShell formulation liraglutide shows a prolonged release with a controlled initial release of liraglutide into the bloodstream. The low initial release is positive and may help mitigate common gastrointestinal side effects like nausea associated with starting GLP-1 treatment.

“Our interim data from the study strengthens our position in business development discussions”, says David Westberg, CEO of Nanexa. “We look forward to presenting the complete Phase 1 study results of NEX-22, that we consider being a unique long-acting GLP-1 formulation with great market potential”.

Clinicaltrials.gov NCT06439056

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

All patients in Nanexa Phase 1 study of NEX-22 dosed according to plan

Datum 2024-10-01, kl 13:00
Källa MFN
Bifogade filer
All patients in Nanexa Phase 1 study of NEX-22 dosed according to plan
Affiliate
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet